RN45'106

Access DB# _____

RECEIVED
JUN 29 2001
STIC

SEARCH REQUEST FORM

Scientific and Technical Information Center

Requester's Full Name: JANE ZARA Examiner #: 77512 Date: 6/28/01
Art Unit: 1635 Phone Number 306-5820 Serial Number: 09/684,061
Mail Box and Bldg/Room Location: 11D03 Results Format Preferred (circle): PAPER DISK E-MAIL
1/E12

If more than one search is submitted, please prioritize searches in order of need.

****

Please provide a detailed statement of the search topic, and describe as specifically as possible the subject matter to be searched. Include the elected species or structures, keywords, synonyms, acronyms, and registry numbers, and combine with the concept or utility of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc, if known. Please attach a copy of the cover sheet, pertinent claims, and abstract.

Title of Invention: AS Comp's & Cancer Treat. Method

Inventors (please provide full names): BARTEL ET AL.

Earliest Priority Filing Date: 10/6/00

For Sequence Searches Only *Please include all pertinent information (parent, child, divisional, or issued patent numbers) along with the appropriate serial number.*

Please Search Seq ID
No 1.

Please limit to 60 NT's.

THANKS

Point of Contact:
Mona Smith
Technical Info. Specialist
CM1 12C14 Tel: 308-3278

Seq. 1

****

STAFF USE ONLY	Type of Search	Vendors and cost where applicable
Searcher: M. Smith	NA Sequence (#) 1	STN
Searcher Phone #:	AA Sequence (#)	Dialog
Searcher Location:	Structure (#)	Questel/Orbit
Date Searcher Picked Up: 7/2/01	Bibliographic	Dr.Link
Date Completed: 7/5/01	Litigation	Lexis/Nexis
Searcher Prep & Review Time: 5	Fulltext	Sequence Systems
Clerical Prep Time:	Patent Family	WWW/Internet
Online Time: 7	Other	Other (specify)

7/2/01 /1 B5903
7/3 Cole

PTO-1590 (1-2000)

09/684,061

Set	Items	Description
S1	0	STEM (S) INFUS$ (S) CIRCULA$
S2	0	(EX ADJ VIVO) (S) STEM
S3	3	(EX VIVO) (S) STEM
S4	3	RD (unique items)

>>>KWIC option is not available in file(s): 399

4/3,K/1 (Item 1 from file: 34)
DIALOG(R)File 34:SciSearch(R) Cited Ref Sci
(c) 2002 Inst for Sci Info. All rts. reserv.

09855075 Genuine Article#: 457XL No. References: 65
Title: Stem cell factor: Biology and relevance to clinical practice
Author(s): Smith MA; Pallister CJ; Smith JG (REPRINT)
Corporate Source: Royal United Hosp NHS Trust,Dept Haematol,Combe Pk/Bath BA1 3NG/Avon/England/ (REPRINT); Royal United Hosp NHS Trust,Dept Haematol,Bath BA1 3NG/Avon/England/; Univ W England,Ctr Biomed Res,Bristol BS16 1QY/Avon/England/
Journal: ACTA HAEMATOLOGICA, 2001, V105, N3, P143-150
ISSN: 0001-5792 Publication date: 20010000
Publisher: KARGER, ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
Language: English Document Type: ARTICLE (ABSTRACT AVAILABLE)

4/3,K/2 (Item 2 from file: 34)
DIALOG(R)File 34:SciSearch(R) Cited Ref Sci
(c) 2002 Inst for Sci Info. All rts. reserv.

07586050 Genuine Article#: 185BR No. References: 42
Title: Bone morphogenetic proteins regulate the developmental program of human hematopoietic stem cells
Author(s): Bhatia M (REPRINT) ; Bonnet D; Wu DM; Murdoch B; Wrana J; Gallacher L; Dick JE
Corporate Source: JOHN P ROBARTS RES INST,DEPT GENE THERAPY & MOL VIROL, 100 PERTH DR/LONDON/ON N6A 5K8/CANADA/ (REPRINT); UNIV WESTERN ONTARIO,DEPT MICROBIOL & IMMUNOL/LONDON/ON N6A 5K8/CANADA/; HOSP SICK CHILDREN,PROGRAM CANC BLOOD/TORONTO/ON M5G 1X8/CANADA/; HOSP SICK CHILDREN,RES INST, PROGRAM DEV BIOL/TORONTO/ON M5G 1X8/CANADA/; UNIV TORONTO,DEPT MOL & MED GENET/TORONTO/ON M5G 1X8/CANADA/
Journal: JOURNAL OF EXPERIMENTAL MEDICINE, 1999, V189, N7 (APR 5), P 1139-1147
ISSN: 0022-1007 Publication date: 19990405
Publisher: ROCKEFELLER UNIV PRESS, 1114 FIRST AVE, 4TH FL, NEW YORK, NY 10021
Language: English Document Type: ARTICLE (ABSTRACT AVAILABLE)

4/3,K/3 (Item 3 from file: 34)
DIALOG(R)File 34:SciSearch(R) Cited Ref Sci
(c) 2002 Inst for Sci Info. All rts. reserv.

03640496 Genuine Article#: PU149 No. References: 19
Title: PRODUCTION OF FUNCTIONAL MYELOID CELLS FROM CD34-SELECTED HEMATOPOIETIC PROGENITOR CELLS USING A CLINICALLY RELEVANT EX-VIVO EXPANSION SYSTEM
Author(s): LILL MC; LYNCH M; FRASER JK; CHUNG GY; SCHILLER G; GLASPY JA; SOUZA L; BALDWIN GC; GASSON JC
Corporate Source: UNIV CALIF LOS ANGELES,SCH MED,DEPT MED,DIV HEMATOL ONCOL,11-934 FACTOR/LOS ANGELES//CA/90024; UNIV CALIF LOS ANGELES,SCH MED,DEPT MED,DIV HEMATOL ONCOL/LOS ANGELES//CA/90024; JONSSON COMPREHENS CANC CTR/LOS ANGELES//CA/00000; AMGEN CORP/THOUSAND OAKS//CA/91320; UNIV CALIF LOS ANGELES,SCH MED,DEPT BIOL CHEM/LOS ANGELES//CA/90024; UNIV CALIF LOS ANGELES,SCH MED,INST MOLEC BIOL/LOS ANGELES//CA/90024
Journal: STEM CELLS, 1994, V12, N6 (NOV), P626-637
ISSN: 1066-5099

Language: ENGLISH Document Type: ARTICLE (Abstract Available)

Set	Items	Description
S1	0	STEM (S) INFUS$ (S) CIRCULA$
S2	0	(EX ADJ VIVO) (S) STEM
S3	3	(EX VIVO) (S) STEM
S4	3	RD (unique items)
S5	1	(EX VIVO) (S) ANTISENSE

>>>KWIC option is not available in file(s): 399

5/3,K/1 (Item 1 from file: 34)

DIALOG(R)File 34:SciSearch(R) Cited Ref Sci

07618466 Genuine Article#: 188DG No. References: 35

Title: Antisense oligonucleotides: local delivery enhances their therapeutic potential

Author(s): Nyce JW (REPRINT)

Corporate Source: EPIGENESIS PHARMACEUT INC,DEPT MOL PHARMACOL & THERAPEUT/PRINCETON//NJ/08543 (REPRINT)

Journal: EXPERT OPINION ON THERAPEUTIC PATENTS, 1999, V9, N3 (MAR), P 263-267

ISSN: 1354-3776 Publication date: 19990300

Publisher: ASHLEY PUBL LTD, 1ST FL, THE LIBRARY, 1 SHEPHERDS HILL HIGHGATE, LONDON N6 5QJ, ENGLAND

Language: English Document Type: REVIEW (ABSTRACT AVAILABLE)

?

[0093] The foregoing methods and compositions also are useful for ex vivo expansion of stem cells after transfection with retroviral or other vectors containing a heterologous nucleic acid (e.g.,
an antisense oligonucleotide, a nucleic acid encoding a therapeutic protein or peptide) for gene therapy applications. Stem cells into which a heterologous nucleic acid has been introduced ex
vivo can be introduced into the subject using the known methods for implanting transfected cells into a human for gene therapy. See, e.g., U.S. Pat. No. 5,399,346 ("Gene Therapy") issued to
Anderson et al.; PCT International application no. PCT/US92/01890 (Publication No. WO 92/15676, "Somatic Cell Gene Therapy", claiming priority to U.S. Ser. No. 667,169, filed Mar. 8, 1991,
inventor I. M. Verma); PCT International application no. PCT/US89/05575 (Publication No. WO 90/06997, "Genetically Engineered Endothelial Cells and Use Thereof", claiming priority to U.S. Ser.
No. 283,586, filed Dec. 8, 1989, inventors Anderson, W. F. et al.).

6,068,836

5,665,350

6,255,112

6,258,597

File 5:Biosis Previews(R) 1969-2001/Jul W3
(c) 2001 BIOSIS
File 6:NTIS 1964-2001/Aug W1
Comp&distr 2000 NTIS, Intl Cpyrght All Right
File 8:Ei Compendex(R) 1970-2001/Jul W3
(c) 2001 Engineering Info. Inc.
File 34:SciSearch(R) Cited Ref Sci 1990-2001/Jul W4
(c) 2001 Inst for Sci Info
File 65:Inside Conferences 1993-2001/Jul W3
(c) 2001 BLDSC all rts. reserv.
File 71:ELSEVIER BIOBASE 1994-2001/Jul W3
(c) 2001 Elsevier Science B.V.
File 73:EMBASE 1974-2001/Jul W3
(c) 2001 Elsevier Science B.V.
File 76:Life Sciences Collection 1982-2001/May
(c) 2001 Cambridge Sci Abs
File 94:JICST-EPlus 1985-2001/Jun W4
(c)2001 Japan Science and Tech Corp(JST)
File 98:General Sci Abs/Full-Text 1984-2001/Jun
(c) 2001 The HW Wilson Co.
File 99:Wilson Appl. Sci & Tech Abs 1983-2001/Jun
(c) 2001 The HW Wilson Co.
File 143:Biol. & Agric. Index 1983-2001/Jun
(c) 2001 The HW Wilson Co
File 144:Pascal 1973-2001/Jul W3
(c) 2001 INIST/CNRS
File 155:MEDLINE(R) 1966-2001/Jul W5
(c) format only 2001 Dialog Corporation
File 172:EMBASE Alert 2001/Jul W3
(c) 2001 Elsevier Science B.V.
File 266:FEDRIP 2001/Jun
Comp & dist by NTIS, Intl Copyright All Rights Res
File 315:ChemEng & Biotec Abs 1970-2001/May
(c) 2001 DECHEMA
File 357:Derwent Biotechnology Abs 1982-2001/Aug B1
(c) 2001 Derwent Publ Ltd
File 358:Current BioTech Abs 1983-2001/May
(c) 2001 DECHEMA
File 369:New Scientist 1994-2001/Jul W1
(c) 2001 Reed Business Information Ltd.
File 370:Science 1996-1999/Jul W3
(c) 1999 AAAS
File 399:CA SEARCH(R) 1967-2001/UD=13504
(c) 2001 AMERICAN CHEMICAL SOCIETY
File 434:SciSearch(R) Cited Ref Sci 1974-1989/Dec
(c) 1998 Inst for Sci Info
File 40:Enviroline(R) 1975-2001/May
(c) 2001 Congressional Information Service
File 41:Pollution Abs 1970-2001/Aug
(c) 2001 Cambridge Scientific Abstracts
File 50:CAB Abstracts 1972-2001/Jun
(c) 2001 CAB International
File 68:Env.Bib. 1974-2001/Jun
(c) 2001 Internl Academy at Santa Barbara
File 77:Conference Papers Index 1973-2001/Jul
(c) 2001 Cambridge Sci Abs
File 103:Energy SciTec 1974-2001/Jul B1
(c) 2001 Contains copyrighted material
File 156:Toxline(R) 1965-2000/Dec
(c) format only 2000 The Dialog Corporation
File 162:CAB HEALTH 1983-2001/Jun
(c) 2001 CAB INTERNATIONAL
File 305:Analytical Abstracts 1980-2001/Jul W1
(c) 2001 Royal Soc Chemistry
File 35:Dissertation Abs Online 1861-2001/Jul
(c) 2001 ProQuest Info&Learning
File 48:SPORTDiscus 1962-2001/Jun
(c) 2001 Sport Information Resource Centre

```
File  91:MANTIS(TM) 1880-2000/Apr
         1999 (c) Action Potential
File 149:TGG Health&Wellness DB(SM) 1976-2001/Jul W2
         (c) 2001 The Gale Group
File 151:HealthSTAR 1975-2000/Dec
         (c) format only 2000 The Dialog Corporation
File 157:Aidsline(R) 1980-2000/Dec
         (c) format only 2000 The Dialog Corporation
File 159:Cancerlit 1975-2001/Jun
         (c) format only 2001 Dialog Corporation
File 164:Allied & Complementary Medicine 1984-2001/Aug
          (c) 2001 BLHCIS
File 442:AMA  Journals 1982-2001/Jul B1
         (c)2001 Amer Med Assn -FARS/DARS apply
File 444:New England Journal of Med. 1985-2001/Jul W4
         (c) 2001 Mass. Med. Soc.
File 457:The Lancet 1986-2000/Oct W1
         (c) 2000 The Lancet, Ltd.
File 467:ExtraMED(tm) 2000/Dec
         (c) 2001 Informania Ltd.

Set     Items   Description
S1        180   EVI(3N)ZINC(W)FINGER
S2          5   S1(S)(ANTISENSE OR RIBOZYME?)
S3          5   RD (unique items)
```

File Copy

01146446 97611956
Molecular mechanism of blastic crisis in chronic myelocytic leukemia. (Meeting abstract).
Mitani K
Third Department of Internal Medicine, Faculty of Medicine, University of Tokyo, Bunkyo ku, Tokyo 113, Japan
Non-serial; Leukemia and Lymphoma, Pathogenesis and Treatment, Molecular Aspects, p. 37. 18th Symposium of the International Association for Competitive Research on Leukemia and Related Diseases, Kyoto, Japan, October 29-November 3, 1995.: 1995
Languages: ENGLISH
Document Type: MEETING ABSTRACTS

... EVI-1 fusion protein of 180 kD containing amino-terminal half of AML1 including a runt homology domain which is fused to the entire of *zinc* *finger* *EVI* -1 protein. Thus, AML1/EVI-1 fusion protein is a chimeric transcription factor including a runt homology domain from AML1 and two *zinc* *finger* domains from *EVI*-1, totally three DNA binding domains, and an acidic domain from EVI-1. To evaluate the effect of the AML1/EVI-1 fusion protein on cell growth of SKH1 cells, we prepared the synthetic *antisense* oligonucleotides with 18 nucleotides spanning the junction point between AML1 and EVI-1 sequences and those with 4 point mutations in their sequences as a negative control. The *antisense* oligonucleotides suppressed 3H-thymidine incorporation in SKH1 cells and decreased the cell number of the cells in comparison with those including 4 point mutations, suggesting...

...AML1/EVI-1 into Rat1 clones harboring BCR/ABL conferred enhanced ability for anchorage independent growth. The analysis using deletion mutants showed that the second *zinc* *finger* domain within the *EVI*-1 was the functional region critical for transformation. The AML1/EVI-1 stimulated AP-1 activity through the TRE site as in the EVI-1...

3/3,K/4 (Item 2 from file: 159)
DIALOG(R)File 159:Cancerlit
(c) format only 2001 Dialog Corporation. All rts. reserv.

01061406 96604994
Oncogenic potentials of the AML-1/EVI-1 fusion protein derived from the t(3;21) (q26;q22) translocation in blastic crisis of chronic myelocytic leukemia (Meeting abstract).
Mitani K; Kurokawa M; Ogawa S; Tanaka T; Yazaki Y; Hirai H
Third Dept. of Internal Medicine, Faculty of Medicine, Univ. of Tokyo, Tokyo, Japan
Blood; 84(10, Suppl 1):229a 1994 ISSN 0903-1936
Languages: ENGLISH
Document Type: JOURNAL ARTICLE

... 1 fusion protein of 180 kD containing amino-terminal half of AML-1 including a runt homology domain which is fused to the entire of *zinc* *finger* *EVI* -1 protein (Mitani K et al, EMBO J; 13:504 1994). Thus AML-1/EVI-1 fusion protein is a chimeric transcription factor including a runt homology domain from AML-1 and two *zinc* *finger* domains from *EVI* -1, totally three DNA binding domains, and an acidic domain from EVI-1 as a transcriptional activation domain. To evaluate the effects of the AML-1/EVI-1 fusion protein on cell growth of SKH-1 cells, we prepared the synthetic *antisense* oligonucleotides with 16 nucleotides spanning the junction point between AML-1 and EVI-1 sequences and those with 4 point mutations in their sequences as a negative control. The *antisense* oligonucleotides suppressed 3H-thymidine incorporation in SKH1 cells and decreased the cell number of the cells in comparison with those including 4 point mutations, suggesting...

...EVI-1 into Rat-1 clones harboring BCR/ABL conferred enhanced ability for anchorage independent growth. The analysis using deletion mutants showed that the second *zinc* *finger* domain within the *EVI* -1 was the functional region critical for transformation. All these data suggest that

the AML-1/EVI-1 could play an important role in leukemic...

App

Copies

3/3,K/5 (Item 3 from file: 159)
DIALOG(R)File 159:Cancerlit

00987458 95699358
Generation of the AML1/EVI-1 fusion gene in the t(3;21)(q26;q22) translocation causes blastic crisis of chronic myelocytic leukemia (Meeting abstract).
Mitani K; Ogawa S; Miyoshi H; Mano H; Yazaki Y; Ohki M; Hirai H
Univ. of Tokyo, Tokyo, Japan
Non-serial; Molecular Biology of Hematopoiesis; 8th Symposium. July 9-13, 1993, Basel, Switzerland, p. 79, 1993.: 1993
Languages: ENGLISH
Document Type: JOURNAL ARTICLE

... cells carrying t(3;21). The fusion protein contains amino-terminal half of AML1 including a runt homology domain which is fused to the entire *zinc* *finger* *EVI* -1 protein. The AML1/EVI-1 fusion has been demonstrated to be consistent among all three cases of the t(3;21)-carrying leukemia. Synthetic *antisense* oligonucleotides with 20 nucleotides spanning the initiation sites of AML1 or EVI-1 sequences suppress 3H-thymidine incorporation in SKH1 cells, suggesting that the AML1...
?

+ cc

Set	Items	Description
S1	180	EVI(3N)ZINC(W)FINGER
S2	5	S1(S)(ANTISENSE OR RIBOZYME?)
S3	5	RD (unique items)

>>>KWIC option is not available in file(s): 41, 77, 399

3/3,K/1 (Item 1 from file: 94)

DIALOG(R)File 94:JICST-EPlus

02664091 JICST ACCESSION NUMBER: 96A0132126 FILE SEGMENT: JICST-E

Analysis of molecular mechanism in blastic crisis of chronic myelocytic leukemia.

MITANI KINUKO (1)
(1) Univ. of Tokyo, Fac. of Med.

Nissan Kagaku Shinko Zaidan Kenkyu Hokokusho(Research Projects in Review, Nissan Science Foundation), 1995, VOL.18(1995), PAGE.235-238, REF.6
JOURNAL NUMBER: X0726AAW ISSN NO: 0911-4572
UNIVERSAL DECIMAL CLASSIFICATION: 616-006-09
LANGUAGE: Japanese COUNTRY OF PUBLICATION: Japan
DOCUMENT TYPE: Journal
ARTICLE TYPE: Short Communication
MEDIA TYPE: Printed Publication

...ABSTRACT: AML1/EVI-1 fusion protein of 180kD containing amino-terminal half of AML1 including a runt homology domain which is fused to the entire of *zinc* *finger* *EVI*-1 protein. Thus, the AML1/EVI-1 fusion protein is a chimeric transcription factor including a runt homology domain from AML1 and two *zinc* *finger* domains from *EVI*-1, totally three DNA binding domains, and an acidic domain from EVI-1. To evaluate the effect of the AML1/EVI-1 fusion protein on cell growth of SKH1 cells, we prepared the synthetic *antisense* oligonucleotides with 18 nucleotides spanning the junction point between AML1 and EVI-1 sequences and those with 4 point mutations in their sequences as a negative control. The *antisense* oligonucleotides suppressed 3H-thymidine incorporation in SKH1 cells and decreased the cell number of the cells in comparison with those including 4 point mutations, suggesting...

...AML1/EVI-1 into Rat1 clones harboring BCR/ABL conferred enhanced ability for anchorage independent growth. The analysis using deletion mutants showed that the second *zinc* *finger* domain within the *EVI*-1 was the functional region critical for transformation. The AML1/EVI-1 could stimulate AP-1 activity through the TRE site as in the EVI...

3/3,K/2 (Item 1 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)

134294085 CA: 134(21)294085d PATENT

Hematopoietic stem cells (HSC) treated with antisense oligonucleotide targeted to genes preferentially expressed in HSC and cancer treatment

INVENTOR(AUTHOR): Bartelmez, Stephen H.; Iversen, Patrick L.
LOCATION: USA
ASSIGNEE: Avi Biopharma, Inc.

PATENT: PCT International ; WO 0125422 A2 DATE: 20010412
APPLICATION: WO 2000US27636 (20001006) *US PV158340 (19991007)
PAGES: 36 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: C12N-015/11A; A61K-031/712B; C12N-005/10B DESIGNATED COUNTRIES: AU; CA; JP; KR
DESIGNATED REGIONAL: AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LU; MC; NL; PT; SE

3/3,K/3 (Item 1 from file: 159)

DIALOG(R)File 159:Cancerlit

01146446 97611956
Molecular mechanism of blastic crisis in chronic myelocytic leukemia. (Meeting abstract).
Mitani K
Third Department of Internal Medicine, Faculty of Medicine, University of Tokyo, Bunkyo ku, Tokyo 113, Japan
Non-serial; Leukemia and Lymphoma, Pathogenesis and Treatment, Molecular Aspects, p. 37. 18th Symposium of the International Association for Competitive Research on Leukemia and Related Diseases, Kyoto, Japan, October 29-November 3, 1995.: 1995
Languages: ENGLISH
Document Type: MEETING ABSTRACTS

... EVI-1 fusion protein of 180 kD containing amino-terminal half of AML1 including a runt homology domain which is fused to the entire of *zinc* *finger* *EVI* -1 protein. Thus, AML1/EVI-1 fusion protein is a chimeric transcription factor including a runt homology domain from AML1 and two *zinc* *finger* domains from *EVI*-1, totally three DNA binding domains, and an acidic domain from EVI-1. To evaluate the effect of the AML1/EVI-1 fusion protein on cell growth of SKH1 cells, we prepared the synthetic *antisense* oligonucleotides with 18 nucleotides spanning the junction point between AML1 and EVI-1 sequences and those with 4 point mutations in their sequences as a negative control. The *antisense* oligonucleotides suppressed 3H-thymidine incorporation in SKH1 cells and decreased the cell number of the cells in comparison with those including 4 point mutations, suggesting...

...AML1/EVI-1 into Rat1 clones harboring BCR/ABL conferred enhanced ability for anchorage independent growth. The analysis using deletion mutants showed that the second *zinc* *finger* domain within the *EVI*-1 was the functional region critical for transformation. The AML1/EVI-1 stimulated AP-1 activity through the TRE site as in the EVI-1...

3/3,K/4 (Item 2 from file: 159)
DIALOG(R)File 159:Cancerlit

01061406 96604994
Oncogenic potentials of the AML-1/EVI-1 fusion protein derived from the t(3;21) (q26;q22) translocation in blastic crisis of chronic myelocytic leukemia (Meeting abstract).
Mitani K; Kurokawa M; Ogawa S; Tanaka T; Yazaki Y; Hirai H
Third Dept. of Internal Medicine, Faculty of Medicine, Univ. of Tokyo, Tokyo, Japan
Blood; 84(10, Suppl 1):229a 1994 ISSN 0903-1936
Languages: ENGLISH
Document Type: JOURNAL ARTICLE

... 1 fusion protein of 180 kD containing amino-terminal half of AML-1 including a runt homology domain which is fused to the entire of *zinc* *finger* *EVI* -1 protein (Mitani K et al, EMBO J; 13:504 1994). Thus AML-1/EVI-1 fusion protein is a chimeric transcription factor including a runt homology domain from AML-1 and two *zinc* *finger* domains from *EVI* -1, totally three DNA binding domains, and an acidic domain from EVI-1 as a transcriptional activation domain. To evaluate the effects of the AML-1/EVI-1 fusion protein on cell growth of SKH-1 cells, we prepared the synthetic *antisense* oligonucleotides with 16 nucleotides spanning the junction point between AML-1 and EVI-1 sequences and those with 4 point mutations in their sequences as a negative control. The *antisense* oligonucleotides suppressed 3H-thymidine incorporation in SKH1 cells and decreased the cell number of the cells in comparison with those including 4 point mutations, suggesting...

...EVI-1 into Rat-1 clones harboring BCR/ABL conferred enhanced ability for anchorage independent growth. The analysis using deletion mutants showed that the second *zinc* *finger* domain within the *EVI* -1 was the functional region critical for transformation. All these data suggest that

the AML-1/EVI-1 could play an important role in leukemic...

3/3,K/5 (Item 3 from file: 159)
DIALOG(R)File 159:Cancerlit

00987458 95699358
Generation of the AML1/EVI-1 fusion gene in the t(3;21)(q26;q22) translocation causes blastic crisis of chronic myelocytic leukemia (Meeting abstract).
Mitani K; Ogawa S; Miyoshi H; Mano H; Yazaki Y; Ohki M; Hirai H
Univ. of Tokyo, Tokyo, Japan
Non-serial; Molecular Biology of Hematopoiesis, 8th Symposium. July 9-13, 1993, Basel, Switzerland, p. 79, 1993.: 1993
Languages: ENGLISH
Document Type: JOURNAL ARTICLE

... cells carrying t(3;21). The fusion protein contains amino-terminal half of AML1 including a runt homology domain which is fused to the entire *zinc* *finger* *EVI* -1 protein. The AML1/EVI-1 fusion has been demonstrated to be consistent among all three cases of the t(3;21)-carrying leukemia. Synthetic *antisense* oligonucleotides with 20 nucleotides spanning the initiation sites of AML1 or EVI-1 sequences suppress 3H-thymidine incorporation in SKH1 cells, suggesting that the AML1...
?

```
?show files;ds;t/3,k/all
File   5:Biosis Previews(R) 1969-2002/Dec W4
         (c) 2002 BIOSIS
File   6:NTIS 1964-2002/Dec W4
         (c) 2002 NTIS, Intl Cpyrght All Rights Res
File  34:SciSearch(R) Cited Ref Sci 1990-2002/Dec W5
         (c) 2002 Inst for Sci Info
File  40:Enviroline(R) 1975-2002/Nov
File  50:CAB Abstracts 1972-2002/Nov
         (c) 2002 CAB International
File  65:Inside Conferences 1993-2002/Dec W4
         (c) 2002 BLDSC all rts. reserv.
File  68:Env.Bib. 1972-2002/Jun
         (c) 2002 Internl Academy at Santa Barbara
File  71:ELSEVIER BIOBASE 1994-2002/Dec W4
         (c) 2002  Elsevier Science B.V.
File  73:EMBASE 1974-2002/Dec W4
         (c) 2002 Elsevier Science B.V.
File  94:JICST-EPlus 1985-2002/Oct W3
         (c)2002 Japan Science and Tech Corp(JST)
File  98:General Sci Abs/Full-Text 1984-2002/Nov
         (c) 2002 The HW Wilson Co.
File 103:Energy SciTec 1974-2002/Dec B1
         (c) 2002 Contains copyrighted material
File 143:Biol. & Agric. Index 1983-2002/Nov
         (c) 2002 The HW Wilson Co
File 144:Pascal 1973-2002/Dec W4
         (c) 2002 INIST/CNRS
File 155:MEDLINE(R) 1966-2002/Nov W4
File 156:ToxFile 1965-2002/Nov W3
         (c) format only 2002 The Dialog Corporation
File 162:CAB Health 1983-2002/Nov
         (c) 2002 CAB International
File 172:EMBASE Alert 2002/Dec W4
         (c) 2002 Elsevier Science B.V.
File 305:Analytical Abstracts 1980-2002/Dec W2
         (c) 2002 Royal Soc Chemistry
File 369:New Scientist 1994-2002/Dec W3
         (c) 2002 Reed Business Information Ltd.
File 370:Science 1996-1999/Jul W3
         (c) 1999 AAAS
File 399:CA SEARCH(R) 1967-2002/UD=13726
         (c) 2002 American Chemical Society
File 434:SciSearch(R) Cited Ref Sci 1974-1989/Dec
         (c) 1998 Inst for Sci Info
File   8:Ei Compendex(R) 1970-2002/Dec W3
         (c) 2002 Elsevier Eng.  Info. Inc.
File  99:Wilson Appl. Sci & Tech Abs 1983-2002/Nov
         (c) 2002 The HW Wilson Co.
File 135:NewsRx Weekly Reports 1995-2002/Dec W4
         (c) 2002 NewsRx
File 266:FEDRIP 2002/Nov
         Comp & dist by NTIS, Intl Copyright All Rights Res
File 315:ChemEng & Biotec Abs 1970-2002/Nov
         (c) 2002 DECHEMA
File 357:Derwent Biotech Res. _1982-2002/Dec W4
         (c) 2002 Thomson Derwent & ISI
File 358:Current BioTech Abs 1983-2002/Nov
          (c) 2002 DECHEMA
File  35:Dissertation Abs Online 1861-2002/Nov
         (c) 2002 ProQuest Info&Learning
File  48:SPORTDiscus 1962-2002/Dec
         (c) 2002 Sport Information Resource Centre
File  91:MANTIS(TM) 1880-2002/Oct
         2002 (c) Action Potential
File 149:TGG Health&Wellness DB(SM) 1976-2002/Dec W2
         (c) 2002 The Gale Group
```

File 159:Cancerlit 1975-2002 ct
(c) format only 2002 Dialog Corporation
File 164:Allied & Complementary Medicine 1984-2002/Dec
(c) 2002 BLHCIS
File 442:AMA Journals 1982-2002/Jan B1
(c)2002 Amer Med Assn -FARS/DARS apply
File 444:New England Journal of Med. 1985-2002/Dec W5
(c) 2002 Mass. Med. Soc.
File 467:ExtraMED(tm) 2000/Dec
(c) 2001 Informania Ltd.

Set	Items	Description
S1	0	STEM (S) INFUS$ (S) CIRCULA$
S2	0	(EX ADJ VIVO) (S) STEM
S3	3	(EX VIVO) (S) STEM
S4	3	RD (unique items)
S5	1	(EX VIVO) (S) ANTISENSE

>>>KWIC option is not available in file(s): 399

5/3,K/1 (Item 1 from file: 34)
DIALOG(R)File 34:SciSearch(R) Cited Ref Sci
(c) 2002 Inst for Sci Info. All rts. reserv.

07618466 Genuine Article#: 188DG No. References: 35
Title: Antisense oligonucleotides: local delivery enhances their therapeutic potential
Author(s): Nyce JW (REPRINT)
Corporate Source: EPIGENESIS PHARMACEUT INC,DEPT MOL PHARMACOL & THERAPEUT/PRINCETON//NJ/08543 (REPRINT)
Journal: EXPERT OPINION ON THERAPEUTIC PATENTS, 1999, V9, N3 (MAR), P 263-267
ISSN: 1354-3776 Publication date: 19990300
Publisher: ASHLEY PUBL LTD, 1ST FL, THE LIBRARY, 1 SHEPHERDS HILL HIGHGATE, LONDON N6 5QJ, ENGLAND
Language: English Document Type: REVIEW (ABSTRACT AVAILABLE)
?
?s antisense (s) infus$

	143120	ANTISENSE
	0	INFUS$
S6	0	ANTISENSE (S) INFUS$